Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in Taiwan

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Country / region: Taiwan Clear all

154 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20031
20042
20053
20062
20077
20083
20096
20106
20119
20128
20133
20148
20154
20166
20174
20188
20197
20209
20218
20229
20238
202410
202512
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed95
Recruiting23
Unknown status22
Terminated5
Not yet recruiting4
Active, not recruiting3
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca15
Boehringer Ingelheim14
Fu Jen Catholic University13
Chang Gung Memorial Hospital10
GlaxoSmithKline10
National Taiwan University Hospital7
Novartis Pharmaceuticals7
Fu Jen Catholic University Hospital6
Chang Gung University4
Far Eastern Memorial Hospital4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive154
Asthma12
Diabetes Mellitus4
Heart Failure4
Lung Diseases4
Lung Diseases, Obstructive3
Respiration Disorders3
Bronchitis, Chronic2
Diabetes Mellitus, Type 22
Dyspnea2

Trials

Showing 1 to 25 of 154. Each trial links to its page on Pharma Observatory.

54 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.